Personalized tobacco treatment in primary care
A multilevel intervention to personalize and improve tobacco treatment in primary care
This study is looking to help people quit smoking by using their genetic information to find the best medications for them, making it easier for both doctors and patients to work together and improve their chances of success.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10874467 on NIH RePORTER |
What this research studies
This research aims to enhance tobacco cessation efforts by personalizing treatment based on genetic markers that influence how individuals respond to cessation medications. It addresses the low rates of medication prescription and usage by physicians and patients, respectively, and seeks to improve treatment effectiveness through a multilevel intervention. By utilizing behavior change theories and focusing on genetic factors, the study aims to motivate both healthcare providers and patients to engage more effectively in cessation efforts. The approach includes matching smokers with the most suitable medications to maximize their chances of quitting successfully.
Who could benefit from this research
Good fit: Ideal candidates for this research are smokers who are seeking help to quit and may benefit from personalized treatment based on their genetic makeup.
Not a fit: Patients who do not smoke or are not interested in quitting tobacco will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized tobacco cessation treatments, significantly improving quit rates among smokers.
How similar studies have performed: Previous research has shown promising results in using genetic markers to guide treatment decisions in smoking cessation, indicating that this approach has potential for success.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Chen, Li-Shiun — Washington University
- Study coordinator: Chen, Li-Shiun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.